Alitretinoin oral - Stiefel Laboratories

Drug Profile

Alitretinoin oral - Stiefel Laboratories

Alternative Names: Alitretinoin - Basilea; BAL4079; Cehado; Once-daily oral alitretinoin - Basilea; Toctino

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Basilea Pharmaceutica; Stiefel Laboratories
  • Class Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Eczema
  • Discontinued Palmoplantar pustulosis; Systemic lupus erythematosus

Most Recent Events

  • 21 Jan 2016 Discontinued - Phase-III for Eczema in USA (PO)
  • 23 Nov 2015 Stiefel acquires distribution rights to Alitretinoin in Europe
  • 12 Mar 2015 Launched for Eczema in South Korea, Slovakia, Romania, Poland, Greece, Malta, Estonia, Bulgaria and Spain (PO) before March 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top